[Nature Communications] Researchers showed that glucocorticoid receptor (GR) and the lysine-specific demethylase 1 (LSD1) interact in myofibers of male mice, and that LSD1 connected GR-bound enhancers with NRF1-associated promoters to stimulate target gene expression.

[Cell Reports] In Max41 transgenic mice, nearly all B cells diverted into the granulocyte lineage. Investigators showed that these mice had an excess of myeloid progenitors, but their common lymphoid progenitor compartment was ablated, and they had few plasmacytoid dendritic cells.

[Journal of Leukocyte Biology] The authors discuss the molecular machinery within the noncanonical NF-κB pathway, crosstalk with the canonical NF-κB pathway, murine models of noncanonical signaling, as well as how aberrations in this pathway manifest in leukemic or hyperinflammatory disease with a focus on Hypereosinophilic syndrome.

[Indiana University School of Medicine (EurekAlert)] A new four-year, $2.7 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases will support the project, “Hypoxia's role in regulating stressed hematopoietic stem cells,” led byIndiana University School of Medicine scientists.

[Heliyon] The expression of homeobox gene B5 (HOXB5) in human osteosarcoma tissues and its correlation with clinical indicators were investigated using bioinformatics analysis and immunohistochemical labelling.

[Stem Cell Research & Therapy] The authors summarize published studies demonstrating donor-sex-related MSC heterogeneity and emphasize the importance of disclosing donor sex as a key factor affecting MSC potency in cell therapy.

[Replay] Replay and The University of Texas MD Anderson Cancer Center announced that the FDA has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for PRAME TCR/IL-15 NK (SY-307) for relapsed/refractory myeloid malignancies.

[Scientific Reports] The authors demonstrated that a combination of p53 inhibition and pro-survival small molecules achieved a homologous recombination rate higher than 90% using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) in human iPSCs.

[Nature Medicine] In this ongoing, open-label Phase II study, 60 biomarker-unselected, treatment-naive patients with resectable NSCLC were randomized to receive two preoperative doses of nivolumab with or without relatlimab antibody therapy.

[Nature Communications] Scientists performed multi-region, single-cell DNA sequencing to characterize the somatic copy number alteration landscape across tumor-rich and normal tissue in two male patients with localized prostate cancer.

[Cancer Research] Researchers identified acyl-CoA synthetase medium chain family members 1 and 3 (ACSM1 and ACSM3) as androgen receptor-regulated mediators of prostate cancer metabolism and growth.

[Molecular Cancer Research] The authors used in vitro and in vivo preclinical MDA prostate cancer PDX models of resistant human prostate cancer to determine molecular mechanisms of cross-resistance between anti-androgen therapy and taxane chemotherapy, underlying the therapeutically resistant phenotype.